Dolasetron mesylate

Main ingredients: Dolasetron mesylate Chemical name: 1H-indole-3-carboxylic acid, octahydro-3-oxo-2,6-methylene-2H-quinolizine-8-(2α, 6α, 8α, 9αβ)-monomethanesulfonate monohydrate. Structural formula: Molecular formula: C19H20N2O3·CH3SO3H·H2O Molecular weight: 438.50 Excipients: mannitol, hydrochloric acid

Because hydrodolasetron is eliminated by multiple pathways, clinically significant drug interactions between dolasetron and hydrodolasetron and commonly used chemotherapy or surgical drugs are unlikely. The most common possible interaction with other drugs is prolongation of the QTc interval. When dolasetron was coadministered with cimetidine (a nonselective inhibitor of cytochrome P-450) for 7 days, the blood concentration of hydrodolasetron increased by 24%, while when it was coadministered with rifampicin (a potent inducer of cytochrome P-450) for 7 days, the blood concentration of hydrodolasetron decreased by 28%. Dolasetron mesylate is safe to be used with chemotherapy and surgical drugs. As with other drugs that prolong the ECG interval, patients should be cautious when taking drugs that prolong the ECG interval, especially the QTc interval. The clearance of hydrodolasetron was not affected in patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy drugs. When dolasetron mesylate was intravenously injected with atenolol, the clearance of hydrogenated dolasetron was reduced by about 27%. Dolasetron mesylate did not affect the patient's anesthesia recovery time. Dolasetron mesylate did not inhibit the anti-tumor activity of the chemotherapy drugs cisplatin, 5-fluorouracil, doxorubicin and cyclophosphamide in mouse models.

Main ingredients: Dolasetron mesylate Chemical name: 1H-indole-3-carboxylic acid, octahydro-3-oxo-2,6-methylene-2H-quinolizine-8-(2α, 6α, 8α, 9αβ)-monomethanesulfonate monohydrate. Structural formula: Molecular formula: C19H20N2O3·CH3SO3H·H2O Molecular weight: 438.50 Excipients: mannitol, hydrochloric acid

Because hydrodolasetron is eliminated by multiple pathways, clinically significant drug interactions between dolasetron and hydrodolasetron and commonly used chemotherapy or surgical drugs are unlikely. The most common possible interaction with other drugs is prolongation of the QTc interval. When dolasetron was coadministered with cimetidine (a nonselective inhibitor of cytochrome P-450) for 7 days, the blood concentration of hydrodolasetron increased by 24%, while when it was coadministered with rifampicin (a potent inducer of cytochrome P-450) for 7 days, the blood concentration of hydrodolasetron decreased by 28%. Dolasetron mesylate is safe to be used with chemotherapy and surgical drugs. As with other drugs that prolong the ECG interval, patients should be cautious when taking drugs that prolong the ECG interval, especially the QTc interval. The clearance of hydrodolasetron was not affected in patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy drugs. When dolasetron mesylate was intravenously injected with atenolol, the clearance of hydrogenated dolasetron was reduced by about 27%. Dolasetron mesylate did not affect the patient's anesthesia recovery time. Dolasetron mesylate did not inhibit the anti-tumor activity of the chemotherapy drugs cisplatin, 5-fluorouracil, doxorubicin and cyclophosphamide in mouse models.